Zacks Research Weighs in on Avantor, Inc.’s Q2 2025 Earnings (NYSE:AVTR)

Avantor, Inc. (NYSE:AVTR) – Stock analysts at Zacks Research raised their Q2 2025 earnings per share estimates for Avantor in a report released on Wednesday, August 28th. Zacks Research analyst D. Dey now forecasts that the company will earn $0.28 per share for the quarter, up from their previous estimate of $0.27. The consensus estimate for Avantor’s current full-year earnings is $1.01 per share. Zacks Research also issued estimates for Avantor’s FY2026 earnings at $1.38 EPS.

Avantor (NYSE:AVTR) last issued its earnings results on Friday, July 26th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.02. Avantor had a return on equity of 12.40% and a net margin of 5.28%. The firm had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.70 billion.

A number of other equities research analysts have also recently weighed in on the company. Barclays lifted their price target on Avantor from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Stifel Nicolaus increased their price target on Avantor from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Monday, July 29th. Morgan Stanley lifted their price objective on shares of Avantor from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Evercore ISI decreased their target price on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Finally, Citigroup downgraded shares of Avantor from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $30.00 to $23.00 in a research report on Wednesday, July 10th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $27.40.

Avantor Trading Up 0.2 %

Shares of NYSE:AVTR opened at $25.84 on Friday. The company has a quick ratio of 1.05, a current ratio of 1.59 and a debt-to-equity ratio of 0.89. The company’s 50-day moving average price is $23.50 and its 200 day moving average price is $24.14. The company has a market cap of $17.55 billion, a PE ratio of 66.26, a P/E/G ratio of 2.71 and a beta of 1.32. Avantor has a fifty-two week low of $16.63 and a fifty-two week high of $28.00.

Hedge Funds Weigh In On Avantor

A number of hedge funds and other institutional investors have recently modified their holdings of AVTR. Jennison Associates LLC boosted its stake in Avantor by 113.0% in the 1st quarter. Jennison Associates LLC now owns 2,497,349 shares of the company’s stock worth $63,857,000 after purchasing an additional 1,325,026 shares during the period. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of Avantor in the fourth quarter worth $2,842,000. BNP Paribas Financial Markets grew its holdings in shares of Avantor by 146.1% during the fourth quarter. BNP Paribas Financial Markets now owns 217,296 shares of the company’s stock valued at $4,961,000 after buying an additional 129,010 shares in the last quarter. Swedbank AB acquired a new position in Avantor during the first quarter valued at $2,707,000. Finally, Diversify Advisory Services LLC purchased a new stake in Avantor in the 1st quarter worth about $908,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.